Effects of the serotonin antagonist amesergide on reproduction in female rats

• Published in: Reproductive toxicology (Elmsford, N.Y.) Vol. 7; no. 6; p. 607
• Main Authors: Seyler, D E, Cohen, I R, Sauter, S
• Format: Journal Article
• Language: English
• Published: United States 01-11-1993
• Subjects: Animals; Animals, Newborn; Animals, Suckling; Behavior, Animal - drug effects; Dose-Response Relationship, Drug; Embryonic and Fetal Development - drug effects; Ergolines - administration & dosage; Ergolines - pharmacology; Female; Fertility - drug effects; Lactation - drug effects; Male; Pregnancy; Pregnancy Outcome; Pregnancy, Animal - drug effects; Rats; Reproduction - drug effects; Serotonin Antagonists - administration & dosage; Serotonin Antagonists - pharmacology; Weight Gain - drug effects
• ISSN: 0890-6238
• DOI: 10.1016/0890-6238(93)90037-8

Amesergide, a serotonin (5-HT2) antagonist intended to treat depression, was administered orally to female CD rats (20/group) at doses of 0, 3, 10, or 30 mg/kg to evaluate effects on mating, fertility, litter size, live birth index (100 x total liveborn progeny/litter size), progeny survival, and weight gain of each litter. The treatment period extended from two weeks prior to mating through postpartum day 21 to cover possible effects of estrous cycle, mating, gestation, and postpartum events. Twenty additional female rats were given 30 mg/kg through gestation day 18, after which they received the acacia vehicle (recovery group). All females were allowed to deliver naturally and rear their progeny. On postpartum day 8, progeny in the control, 30 mg/kg and 30 mg/kg recovery groups were removed from dams for 4 h. Progeny were weighed as litters, returned to the dams for a 1-h nursing period, and then weighed again to provide an indication of milk intake. Mating and fertility, using the present study design, were not affected by treatment with amesergide. No effects were observed on litter size, live birth index, or progeny survival. In contrast, treatment with amesergide throughout gestation and lactation produced a significant dose-related depression in progeny body weight gains. However, when treatment was discontinued after day 18 of gestation (30 mg/kg recovery group), progeny body weight gains did not differ from those of the control group.